News Conference News AHA 2025 Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV Michael O'Riordan November 08, 2025
News Conference News ACC 2024 Need a Statin for Primary Prevention? There’s an App for That Michael O'Riordan April 10, 2024
News Conference News SCAI 2023 Real-World CLTI Patients, Outcomes Are a Departure From BEST-CLI L.A. McKeown May 24, 2023
News Conference News AHA 2022 ‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE Michael O'Riordan November 06, 2022
News Conference News ESC 2021 No Attenuation in CVD Risk Reduction for Patients Treated to Very Low LDLs: FOURIER Michael O'Riordan September 02, 2021
News Conference News ESC 2021 Both Acute and Chronic Myocardial Injury in COVID-19 Impede 6-Month Survival Caitlin E. Cox September 01, 2021
News Conference News AHA 2019 LDL Levels Still Too High in Many Statin-Treated Patients: PINNACLE Michael O'Riordan November 13, 2019
News Conference News VIVA 2018 Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease L.A. McKeown November 15, 2018
News Conference News EAS 2018 ORION 1 Data Show Lipoprotein-Lowering Beyond LDL Cholesterol With Injectable Inclisiran Yael L. Maxwell May 14, 2018
News Conference News ACC 2018 High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab Michael O'Riordan March 20, 2018
News Conference News AHA 2017 Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events Michael O'Riordan November 17, 2017
News Conference News ESC 2017 COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease Todd Neale August 27, 2017
News Conference News ISET 2017 Routine Screening of ABI to Identify PAD: Despite Guidelines, One Expert Asks Why Not? Caitlin E. Cox February 06, 2017
News Conference News TCT 2016 YELLOW II: Improved Cholesterol Efflux Linked to Plaque Stabilization in Statin-Treated Patients Michael O'Riordan October 29, 2016